MedTrace Logo

Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

NCT04919122 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 468

Last updated 2026-02-11

No results posted yet for this study

Summary

ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.

Conditions

  • Metastatic Renal Cell Carcinoma

Sponsors & Collaborators

Principal Investigators

  • Daniel George, MD · Duke University

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04919122 on ClinicalTrials.gov